{"blog": [], "keywords": [{"value": "Eczema", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "3", "is_major": "N"}, {"value": "Sanofi SA", "name": "organizations", "rank": "5", "is_major": "N"}, {"value": "Regeneron Pharmaceuticals Inc", "name": "organizations", "rank": "6", "is_major": "N"}, {"value": "New England Journal of Medicine", "name": "organizations", "rank": "7", "is_major": "Y"}, {"value": "Research", "name": "subject", "rank": "8", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/10/01/health/severe-eczema-atopic-dermatitis-drug.html", "document_type": "article", "byline": {"person": [{"lastname": "KOLATA", "firstname": "Gina", "role": "reported", "organization": "", "rank": 1}], "original": "By GINA KOLATA"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/10/01/science/01SKIN/01SKIN-thumbWide.jpg", "legacy": {"wide": "images/2016/10/01/science/01SKIN/01SKIN-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/10/01/science/01SKIN2/01SKIN2-articleLarge.jpg", "legacy": {"xlarge": "images/2016/10/01/science/01SKIN2/01SKIN2-articleLarge.jpg", "xlargeheight": "438", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 438}, {"url": "images/2016/10/01/science/01SKIN/01SKIN-thumbStandard-v2.jpg", "legacy": {"thumbnail": "images/2016/10/01/science/01SKIN/01SKIN-thumbStandard-v2.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Health", "word_count": "1201", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Atopic dermatitis causes itching so extreme that many patients consider suicide. In trials, most patients said symptoms waned in the first two weeks of taking a new drug.", "pub_date": "2016-10-01T04:00:00+0000", "news_desk": "National", "headline": {"print_headline": "2 Trials Show New Treatment for Severe Eczema Can Provide Swift Relief", "main": "New Drug for Severe Eczema Is Successful in 2 New Trials"}, "print_page": "13", "snippet": "Atopic dermatitis causes itching so extreme that many patients consider suicide. In trials, most patients said symptoms waned in the first two weeks of taking a new drug....", "_id": "57ef510095d0e021d79897e7", "slideshow_credits": null, "abstract": "Results of two large clinical trials of drug dupilumab, developed to treat uncontrolled, moderate-to-severe atopic dermatitis, type of eczema, are published in New England Journal of Medicine; trials show promising results, with some patients experiencing instantaneous relief from itching that can sometimes be so unbearable patients consider suicide."}